Tafluprost acid is the active pharmaceutical ingredient (API) and free acid form of the prostaglandin analog tafluprost. It is a synthetic prostaglandin F2α analog, structurally characterized by the presence of a fluoro substituent at the 15-position of the prostaglandin backbone, which enhances its stability and pharmacological profile. Its primary and well-defined application is in ophthalmology for the treatment of glaucoma and ocular hypertension. As the active metabolite of the prodrug tafluprost (marketed as a preservative-free formulation, e.g., Saflutan®), it functions by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby effectively lowering intraocular pressure. It is a key therapeutic agent for managing conditions that can lead to optic nerve damage and vision loss. This compound is specifically developed and utilized as a high-purity active pharmaceutical substance. Its synthesis and quality control are strictly governed by pharmaceutical manufacturing standards to ensure safety and efficacy in final medicinal products.